Pacira Pharmaceuticals (NASDAQ:PCRX) specializes in non-opioid pain management and regenerative health solutions to improve patients' journeys in acute care and ambulatory settings. Traded on the NASDAQ stock exchange under the ticker code PCRX, the company focuses on pioneering projects aimed at minimizing reliance on opioids for post-surgical pain management. Pacira's flagship product, EXPAREL, exemplifies their commitment to providing innovative, effective pain relief options. With a keen eye on expanding its portfolio, Pacira actively pursues research and development projects alongside strategic acquisitions to broaden its impact on pain management. The overarching objective is to offer safer, more effective alternatives that can significantly alter patient care standards and better respond to the urgent need for opioid alternatives in medical practice.